More on AFMD

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (10.0 Score)
- Holders

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Affimed (NQ:AFMD)
Delayed: 9.89 +0.24 (2.49%)
Prev. Close $9.65  
Open$9.94 
52 Wk High$8.26 
52 Wk Low$1.75 
Day High$10.54 
Day Low$9.71 
P/E N/A  
EPS$0.00 
Volume7,754,220 

Friends, Peers and Foes (?): 0HL9 (more...)

Apr 12, 2021 06:58 AM Affimed Therapeutics (AFMD) PT Raised to $15 at BMO Capital
Apr 12, 2021 06:34 AM Affimed (AFMD) Highlights the Potential of its Innate Cell Engager AFM24 as EGFR-targeting Therapy for Solid Tumors as Monotherapy and in Combination with Adoptive NK Cell Transfer at AACR
Apr 12, 2021 06:30 AM Affimed Highlights the Potential of its Innate Cell Engager AFM24 as EGFR-targeting Therapy for Solid Tumors as Monotherapy and in Combination with Adoptive NK Cell Transfer at AACR Virtual Annual Mee
Apr 12, 2021 06:30 AM Affimed Highlights the Potential of its Innate Cell Engager AFM24 as EGFR-targeting Therapy for Solid Tumors as Monotherapy and in Combination with Adoptive NK Cell Transfer at AACR Virtual Annual Mee
Apr 9, 2021 09:47 AM Increasing unusual call option volume: AFMD LEVI ASO CS
Apr 9, 2021 09:31 AM Pre-Open Stock Movers 04/09: (CELC) (AFMD) (GLSI) Higher; (PRVB) (ITRM) (JKS) Lower (more...)
Apr 9, 2021 06:56 AM Affimed (AFMD) Climbs 40% Following Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13
Apr 9, 2021 06:45 AM Affimed (AFMD) Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13
Apr 9, 2021 06:16 AM Form 6-K Affimed N.V. For: Apr 09
Apr 9, 2021 05:59 AM Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13
View All Articles